Related Experiment Video

Updated: Aug 23, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status

P Zapater1, M C Lasso de la Vega, J F Horga

  • 1Unidad de Farmacología Clínica, Hospital General Universitario, y Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Miguel Hernández, San Juan de Alicante, Spain. zapater_ped@gva.es

Alimentary Pharmacology & Therapeutics
|July 1, 2004
PubMed

Insights

Patients with cirrhosis exhibit altered acetaminophen pharmacokinetics, including higher exposure and lower clearance. Arterial pressure influences acetaminophen levels, highlighting the role of hemodynamics in liver disease.

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Pharmacy

Background:

  • Cirrhosis significantly impacts drug metabolism and elimination.
  • Understanding acetaminophen pharmacokinetics in cirrhosis is crucial for safe and effective pain management.

Purpose of the Study:

  • To investigate the pharmacokinetic and metabolism profiles of acetaminophen in patients with liver cirrhosis.
  • To compare these profiles with those of healthy volunteers.

Main Methods:

  • A single oral dose of acetaminophen (1000 mg) was administered to healthy subjects and patients with varying grades of cirrhosis.
  • Plasma acetaminophen and metabolite levels were quantified using High-Performance Liquid Chromatography (HPLC).

Main Results:

  • Patients with cirrhosis demonstrated a significantly higher area under the concentration-time curve (AUC) and prolonged elimination half-life compared to healthy volunteers.
  • Acetaminophen clearance was markedly reduced in cirrhotic patients.
  • Faster absorption and earlier therapeutic concentrations were observed in patients with oesophageal varices.
  • Lower AUC was associated with lower mean and systolic arterial pressure, irrespective of cirrhosis severity.

Conclusions:

  • Cirrhosis leads to altered acetaminophen pharmacokinetics, characterized by increased exposure and reduced clearance.
  • The presence of oesophageal varices is linked to faster achievement of therapeutic acetaminophen levels.
  • Hemodynamic factors, specifically arterial pressure, play a significant role in acetaminophen pharmacokinetics in patients with cirrhosis.
Abstract

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...